Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction

Journal of Medicinal Chemistry

Volumn 57, Issue 6, 2014, Pages 2472-2488

  Gonzalez, Ana Z ^a   Eksterowicz, John ^a   Bartberger, Michael D ^b   Beck, Hilary P ^a   Canon, Jude ^a   Chen, Ada ^a   Chow, David ^a   Duquette, Jason ^a   Fox, Brian M ^a   Fu, Jiasheng ^a   Huang, Xin ^a   Houze, Jonathan B ^a   Jin, Lixia ^a   Li, Yihong ^a   Li, Zhihong ^a   Ling, Yun ^a   Lo, Mei Chu ^a   Long, Alexander M ^a   McGee, Lawrence R ^a   McIntosh, Joel ^a   McMinn, Dustin L ^a   Oliner, Jonathan D ^a   Osgood, Tao ^a   Rew, Yosup ^a   Saiki, Anne Y ^a   Shaffer, Paul ^a   Wortman, Sarah ^a   Yakowec, Peter ^a   Yan, Xuelei ^a   Ye, Qiuping ^a   Yu, Dongyin ^a   Zhao, Xiaoning ^a   Zhou, Jing ^b   Olson, Steven H ^a   Medina, Julio C ^a   Sun, Daqing ^a   more..

^a AMGEN INC   (United States)

^b Department of Pharmaceutics Amgen Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AM 8735; AMG 232; AMG 8735; MORPHOLINE DERIVATIVE; MORPHOLINONE INHIBITOR; PIPERIDONE DERIVATIVE; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; LIVER CELL; NONHUMAN; OSTEOSARCOMA; PROTEIN PROTEIN INTERACTION; TUMOR XENOGRAFT;

ACETATES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; HUMANS; INDICATORS AND REAGENTS; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MORPHOLINES; PROTO-ONCOGENE PROTEINS C-MDM2; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897396378     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401767k     Document Type: Article

References (40)

1. Levine, A. J. p53, the cellular gatekeeper for growth and division Cell 1997, 88, 323-331
2. Lane, D. P. p53, guardian of the genome Nature 1992, 358, 15-16
3. Toledo, F.; Wahl, G. M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas Nat. Rev. 2006, 909-923
4. Hainaut, P.; Hollstein, M. p53 and human cancers: the first ten thousand mutations Adv. Cancer Res. 2000, 77, 81-137
5. Riedinger, C.; McDonnel, J. M. Inhibitors of MDM2 and MDMX: a structural perspective Future Med. Chem. 2009, 1, 1075-1094
6. Oliner, J. D.; Kinzler, K. W.; Meltzer, P. S.; George, D. L.; Vogelstein, B. Nature 1992, 358, 80-83
7. Chene, P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy Nat. Rev. Cancer 2003, 3, 102-109
8. Vogelstein, B.; Lane, D.; Levine, A. J. Surfing the p53 network Nature (London) 2000, 408, 307-310
9. Chen, J.; Wu, X.; Lin, J.; Levine, A. J. MDM2 inhibits the G1 arrest and apoptosis function of the p53 tumor suppressor protein Mol. Cell. Biol. 1996, 16, 2445-2452
10. Wells, J. A.; McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces Nature 2007, 450, 1001-1009
11. Kussie, P. H.; Gorina, S.; Marcchal, V.; Elenbaas, B.; Moreau, J.; Levine, A. J.; Pavletich, N. P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain Science 1996, 274, 948-953
12. Garcia-Echevarria, C.; Chene, P.; Blommers, M. J. J.; Furet, P. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53 J. Med. Chem. 2000, 43, 3205-3208
13. Arkin, M. R.; Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream Nat. Rev. Drug Discovery 2004, 3, 301-317
14. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. In vivo activation of the p53 pathway by small molecule antagonists of MDM2 Science 2004, 303, 844-848
15. Vu, B. T.; Vassilev, L. Small-molecule inhibitors of the p53-MDM2 interaction Curr. Top. Microbiol. Immunol. 2011, 348, 151-172
16. Parks, D. J.; LaFrance, L. V.; Calvo, R. R.; Milkiewicz, K. L.; Gupta, V.; Lattance, J.; Ramachandren, K.; Carver, T. E.; Petrella, E. C.; Cummings, M. D.; Maguire, D.; Grasberger, B. L.; Lu, T. 1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR Bioorg. Med. Chem. Lett. 2005, 15, 765-770
17. Parks, D. J.; LaFrance, L. V.; Calvo, R. R.; Milkiewicz, K. L.; Marugan, J. L.; Raboisson, P.; Schubert, C.; Koblish, H. K.; Zhao, S.; Franks, C. F.; Lattanze, J.; Carver, T. E.; Cummings, M. D.; Maguire, D.; Grasberger, B. L.; Maroney, A. C.; Lu, T. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design Bioorg. Med. Chem. Lett. 2006, 16, 3310-3314
18. Grasberger, B. L.; Lu, T.; Schubert, C.; Parks, D. J.; Carver, T. E.; Koblish, H. K.; Cummings, M. D.; LaFrance, L. V.; Milkiewicz, K. L.; Calvo, R. R.; Maguire, D.; Lattanze, J.; Franks, C. F.; Zhao, S.; Ramachandren, K.; Bylebyl, G. R.; Zhang, M.; Manthey, C. L.; Petrella, E. C.; Pantoliano, M. W.; Deckman, I. C.; Spurlino, J. C.; Maroney, A. C.; Tomczuk, B. E.; Molloy, C. J.; Bone, R. F. Discovery and co-crystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells J. Med. Chem. 2005, 48, 909-912
19. Huang, Y.; Wolf, S.; Bista, M.; Meireles, L.; Camacho, C.; Holak, T. A.; Domling, A. 1,4-Thienodiazepine-2,5-diones via MCR (I): synthesis, virtual space and p53-Mdm2 activity Chem. Biol. Drug Des. 2010, 76, 116-129
20. Ding, K.; Lu, Y.; Nikolovska-Coleska, Z.; Wang, G.; Qiu, S.; Shangary, S.; Gao, W.; Qin, D.; Stuckey, J.; Krajewski, K.; Roller, P. P.; Wang, S. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction J. Med. Chem. 2006, 49, 3432-3435
21. Yu, S.; Qin, D.; Shangary, S.; Chen, J.; Wang, G.; Ding, K.; McEachern, D.; Qiu, S.; Nikolovska-Coleska, Z.; Miller, R.; Kang, S.; Yang, D.; Wang, S. Potent and orally active small molecule inhibitors of the MDM2-p53 interaction J. Med. Chem. 2009, 52, 7970-7973
22. Wang, S.; Yu, S.; Sun, W.; Shangary, S. K.; Sun, D.; Zou, P.; McEachern, D.; Zhao, Y. Preparation of Spiro-oxindole Derivatives as MDM2 Antagonists. US2011/0112052A1, 2011.
23. Furet, P.; Chène, P.; De Pover, A.; Stachyra Valat, T.; Hergovich Lisztwan, J.; Kallen, J.; Masuya, K. The central valine concept provides an entry in a class of non-peptide inhibitors of the p53-MDM2 interaction Bioorg. Med. Chem. Lett. 2012, 22, 3498
24. RG7112 (Hoffmann-La Roche).
25. RO5503781 (Hoffmann-La Roche).
26. MK-8242 (Merck).
27. SAR405838 (Sanofi).
28. AMG 232 (Amgen).
29. Kamal, A.; Azhar Mohammed, A.; Shaik, T. B. p-53-MDM2 inhibitors: patent review (2009-2010) Expert Opin. Ther. Pat. 2012, 22, 95-105
30. Tovar, C.; Graves, B.; Packman, K.; Filipovic, Z.; Higgins, B.; Xia, M.; Tardell, C.; Garrido, R.; Lee, E.; Kolinsky, K.; To, K.-H.; Linn, M.; Podlaski, F.; Wovkulich, P.; Vu, B.; Vassilev, L. T. MDM2 Small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models Cancer Res. 2013, 73, 2587-2597
31. Ding, Q.; Zhang, Z.; Liu, J.-J.; Jiang, N.; Zhang, J.; Ross, T. M.; Chu, X.-J.; Bartkovitz, D.; Podlaski, F.; Janson, C.; Tovar, C.; Filipovic, Z. M.; Higgins, B.; Glenn, K.; Packman, K.; Vassilev, L. T.; Graves, B. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development J. Med. Chem. 2013, 56, 5979-5983
32. Rew, Y.; Sun, D.; Gonzalez Lopez De Turiso, F.; Bartberger, M. D.; Beck, H. P.; Canon, J.; Chen, A.; Chow, D.; Deignan, J.; Fox, B. M.; Gustin, D.; Huang, X.; Jiang, M.; Jiao, X.; Jin, L.; Kayser, F.; Kopecky, D. J.; Li, Y.; Lo, M.; Long, A. M.; Michelsen, K.; Oliner, J. D.; Osgood, T.; Ragains, M.; Saiki, A. Y.; Schneider, S.; Toteva, M.; Yakowec, P.; Yan, X.; Ye, Q.; Yu, D.; Zhao, X.; Zhou, J.; Medina, J. C.; Olson, S. H. Structure-based design of novel inhibitors of the MDM2-p53 interaction J. Med. Chem. 2012, 55, 4936-4954
33. Lucas, B. S.; Fisher, B.; McGee, L. R.; Olson, S. H.; Medina, J. C.; Cheung, E. An expeditious synthesis of the MDM2-p53 inhibitor AM-8553 J. Am. Chem. Soc. 2012, 134, 12855-12860
34. Sun, D.; Li, Z.; Rew, Y.; Bartberger, M. D.; Beck, H. P.; Canon, J.; Chen, A.; Chen, X.; Chow, D.; Deignan, J.; Duquette, J.; Eksterowicz, J.; Fisher, B.; Fox, B. M.; Fu, J.; Gonzalez, A. Z.; Gonzalez-Lopez De Turiso, F.; Gribble, M.; Houze, J.; Huang, X.; Jiang, M.; Jin, L.; Kayser, F.; Liu, J.; Lo, M.-C.; Long, A. M.; Lucas, B.; McGee, L. R.; McIntosh, J.; Mihalic, J.; Oliner, J. D.; Osgood, T.; Peterson, M. L.; Roveto, P.; Saiki, A. Y.; Shaffer, P.; Toteva, M.; Wang, Y.; Wang, Y. C.; Wortman, S.; Yakowec, P.; Yan, X.; Ye, Q.; Yu, D.; Yu, M.; Zhao, X.; Zhou, X.; Zhu, J.; Olson, S. H.; Medina, J. C. Discovery of AMG 232, a potent, selective, and orally bioavailable inhibitor of the MDM2-p53 interaction. J. Med. Chem. [Online early access]. DOI: 10.1021/jm401753e. Published Online: Jan 23, 2014.
35. Allen, J. G.; Bourbeau, M. P.; Wohlhieter, G. E.; Bartberger, M. D.; Michelsen, K.; Hungate, R.; Gadwood, R. C.; Gaston, R. D.; Evans, B.; Mann, L. W.; Matison, M. E.; Schneider, S.; Huang, X.; Yu, D.; Andrews, P. S.; Reichelt, A.; Long, A. M.; Yakowec, P.; Yang, E. Y.; Lee, T. A.; Oliner, J. D. Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction J. Med. Chem. 2009, 52, 7044-7053
36. Beck, H. P.; DeGraffenreid, M.; Fox, B.; Allen, J. G.; Rew, Y.; Schneider, S.; Saiki, A. Y.; Yu, D.; Oliner, J. D.; Salyers, K.; Ye, Q.; Olson, S. Improvement of the synthesis and pharmacokinetic properties of chromenotriazolopyrimidine MDM2-p53 protein-protein inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 2752-2755
37. Gonzalez-Lopez de Turiso, F.; Sun, D.; Rew, Y.; Bartberger, M. D.; Beck, H. P.; Canon, J.; Chen, A.; Chow, D.; Correll, T. L.; Huang, X.; Julian, L. D.; Kayser, F.; Lo, M.-C.; Long, A. M.; McMinn, D.; Oliner, J. D.; Osgood, T.; Powers, J. P.; Saiki, A. Y.; Schneider, S.; Shaffer, P.; Xiao, S.-H.; Yakowek, P.; Yan, X.; Ye, Q.; Yu, D.; Zhao, X.; Zhou, J.; Medina, J. C.; Olson, S. H. Rational design and binding mode of MDM2-p53 inhibitors J. Med. Chem. 2013, 56, 4053-4070
38. Intermediate 39e was synthesized through a procedure similar to that published in the following: Bae, J. H.; Shin, S.-H.; Park, C. S.; Lee, W. K. Preparation of cysteinol derivatives by highly regioselective ring opening of non-activated chiral aziridines by thiols Tetrahedron 1999, 55, 10041-10046
39. Peruncheralathan, S.; Henze, M.; Schneider, C. Indium(III) chloride-catalyzed thiolysis of meso-aziridines Tetrahedron Lett. 2007, 48, 6743-6746
40. Tsunoda, T.; Ozaki, F.; Itô, S. Novel reactivity of stabilized methylenetributylphosphorane: a new Mitsunobu reagent Tetrahedron Lett. 1994, 35, 5081-5082